article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

By designing research with participants involved from the start, and with autonomy as a core principle, we can escape from the often binary and paternalistic views that dominate. And if participants have opted in to be made aware of their risks of genetic diseases, then communication has to be carefully considered.

article thumbnail

Leveraging Genetic Testing for Enrolling Rare Disease Trials

Worldwide Clinical Trials

Much of what we discuss I covered in my presentation, “Leveraging Genetics to Support Rare Disease Clinical Trials,” at last year’s World Orphan Drug Congress (WODC) EU. In my capstone, I focused on how, if, and when genetic counselors discuss clinical trials with their patients in the context of a counseling session.

Genetics 168
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Abu Dhabi DoH signs new deal to accelerate development in life sciences

Pharmaceutical Technology

The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance life sciences.

article thumbnail

New drug candidate slows the progression of adrenoleukodystrophy

Medical Xpress

The results are published in The Lancet Neurology.

article thumbnail

Bespoke Gene Therapy Consortium Selects 8 Rare Diseases for Clinical Trial Portfolio

XTalks

Related: Gene Therapy Clinical Trials for Rare Diseases: 5 Key Takeaways from FDA’s Recent Town Hall “The BGTC offers promise for rare disease patients around the world,” said Julie Gerberding, MD, CEO of the FNIH, in the press release from the agency.

article thumbnail

10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases

XTalks

Rare diseases can often be progressive, chronic and fatal. Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. Sadly, one-third of children with rare diseases die before their first birthday.

article thumbnail

Merck Receives Priority Review From FDA for New Drug Application for HIF-2? Inhibitor Belzutifan (MK-6482)

The Pharma Data

“Von Hippel-Lindau disease is a rare genetic condition for which there is no systemic treatment option available and is associated with a high risk of cancer development in multiple organs. Research into VHL biology that led to the discovery of HIF-2? About Von Hippel-Lindau Disease and Renal Cell Carcinoma.

Drugs 52